Does Adalimumab Bwwd Interact with Abatacept?
CDI records a major classification for Adalimumab Bwwd and Abatacept. The stored summary is: Increased risk of serious infection when combined with HADLIMA; not recommended for RA patients. The mechanism involves tnf blocker combined with abatacept increases infection risk. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Adalimumab Bwwd Class
- Tumor Necrosis Factor Blocker
- Abatacept Class
- Selective T Cell Costimulation Modulator
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
TNF blocker combined with abatacept increases infection risk
What To Tell Your Doctor or Pharmacist
If you are taking Adalimumab Bwwd and your doctor is considering prescribing Abatacept (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider